An interventional study of FAMS-T1D and Digital resources for diabetes in Type 1 Diabetes, sponsored by Vanderbilt University Medical Center. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years to 24 Years. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Vanderbilt University Medical Center · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Diabetes Mellitus, Type 1 by Vanderbilt University Medical Center — 5 open to participants now, 6 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Vanderbilt University Medical Center.
Among the 15 studies in Diabetes Mellitus, Type 1 by Vanderbilt University Medical Center, this one is the 5th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2023, is one of 11 with no phase, and was the 10th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →5 of the 15 studies in Diabetes Mellitus, Type 1 by Vanderbilt University Medical Center are open now, in 1 country. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 13–21
Vanderbilt University Medical Center · Sites in United States
Ages 18–60 · Healthy volunteers
Vanderbilt University Medical Center · Sites in United States
Ages 18+
Vanderbilt University Medical Center · Sites in United States
Ages 11–17
Vanderbilt University Medical Center · Sites in United States
Ages 12–50
By country, each count listing its studies:
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 18 Years to 24 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 140 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 50 across the 14 interventional studies, 12 across the 1 observational. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
Vanderbilt University Medical Center is the lead sponsor of 837 studies on the registry; 157 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 92 (73%) have results posted.
6 of the studies in Diabetes Mellitus, Type 1 by Vanderbilt University Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07116434Vanderbilt University Medical CenterDiscovery Diabetes | 2026-11 |
| NCT06852950Vanderbilt University Medical CenterContinuous Glucose Monitoring for Outpatient Diabetes Management After Hospital Discharge | 2027-01 |
| NCT05854069Vanderbilt University Medical CenterAdapting FAMS to Optimize CGM Use Among Emerging Adults With Type 1 Diabetes | 2027-01-31 |
| NCT06338553Vanderbilt University Medical CenterGLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab | 2027-03 |
| NCT06609356Vanderbilt University Medical CenterCardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes | 2027-07 |
Add all 6 to your calendar (.ics) → With an account.
Among the 15 studies in Diabetes Mellitus, Type 1 by Vanderbilt University Medical Center, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate the efficacy of an adapted FAMS (Family/friend Activation to Motivate Self-care) intervention on CGM use among study participants who are CGM users. We will leverage the infrastructure of an NIDDK-funded RCT evaluating FAMS-T1D among N=280 emerging adults with T1D who have elevated hemoglobin A1c or elevated diabetes distress (NCT05820477). We anticipate at least 50% using CGM to be included in these analyses.
FAMS (Family/friend Activation to Motivate Self-care) is a mobile phone-delivered intervention, based on Family Systems Theory, which helps adults with diabetes set behavioral goals and improve support received from friends and family for goal success. FAMS includes monthly phone coaching and text message support by FAMS coaches for the person with diabetes (PWD) and the option to enroll a support person (SP) to receive automated texts tailored to the self-care goals the person with T1D sets in coaching sessions. Adaptations specific to CGM include the option to set CGM use goals in coaching (and receive associated text support) and skill-building exercises during coaching to support data sharing relationships (e.g., establishing, setting and adjusting ground rules about communication).
Within the FAMS-T1D RCT (NCT05820477), we will test effects of FAMS-T1D on CGM use use relative to enhanced treatment as usual. We will evaluate effects on CGM use from baseline to post-intervention (6 months) as the primary endpoint. Study start date for the nested trial (NCT05854069) is the enrollment date of the first participant using a CGM. Since the goal of this trial is to assess effects of the adapted FAMS intervention on CGM use, the date participant CGM usage was confirmed is considered the enrollment date.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
PERSONS WITH DIABETES
SUPPORT PERSONS
Exclusion Criteria:
PERSONS WITH DIABETES
SUPPORT PERSONS
Participants will receive FAMS-T1D components (monthly phone coaching and text message support for goals) for 6 months. Support persons will receive text messages that are tailored to the goal set by the person with type 1 diabetes. All persons with diabetes will receive text messages regarding how to access their HbA1c results and receive links providing information to assist them in self-care behaviors related to their diabetes. All support persons will also receive materials about type 1 diabetes and how to provide helpful support to the person with diabetes.
Behavioral: FAMS-T1D · Behavioral: Digital resources for diabetes
All persons with diabetes will receive text messages regarding how to access their HbA1c results and receive links providing information to assist them in self-care behaviors related to their diabetes. All support persons will also receive materials about type 1 diabetes and how to provide helpful support to the person with diabetes.
Behavioral: Digital resources for diabetes
FAMS-T1D involves monthly phone coaching that assists individuals in setting specific and time bound diabetes goals with automated text message support to the patient participant and less frequent automated text messages to their support person, if one is enrolled. Behavioral: Diabetes Resources High quality digital materials about diabetes management will be provided upon enrollment and send to participants quarterly.
Also known as: Family/friend Activation to Motivate Self-Care for those with Type 1 Diabetes
Quality digital resources about diabetes management provided upon enrollment and during the study.
CGM frequency of use during the intervention period
Change in CGM frequency of use assessed by self-report on questionnaire; more frequent use/higher is better
Time frame: Baseline and 6 months post-baseline
CGM frequency of use during the intervention period
Change in CGM frequency of use assessed by objective CGM data (% of time; higher is better)
Time frame: Baseline and 6 months post-baseline
Gaps in CGM use
Length of gaps in CGM use as assessed by objective CGM data (measured in number of consecutive days without CGM data; higher is worse)
Time frame: 6 months post-baseline
CGM behavioral responses during the intervention period
Change in frequency of making behavioral changes in response to CGM data assessed by self-report; higher scores indicate more frequent response (better)
Time frame: Baseline and 6 months post-baseline
Barriers to CGM use during the intervention period
Change in perceived influence of CGM on glycemic control scale assessed by Glucose Monitoring Survey; higher scores indicate more perceived problems with CGM use (worse)
Time frame: Baseline and 6 months post-baseline
Barriers to CGM use during the intervention period
Change in perceived influence of CGM on social complications assessed by Glucose Monitoring Survey; higher scores indicate more perceived problems with CGM use (worse)
Time frame: Baseline and 6 months post-baseline
CGM satisfaction during the intervention period
Change in CGM satisfaction assessed by Benefits of CGM scale; higher scores indicate more perceived benefits of CGM use (better)
Time frame: Baseline and 6 months post-baseline
Data sharing during the intervention period
Number of data sharing relationships, between groups; more is better
Time frame: 6 months post-baseline
Satisfaction with data-sharing relationships
Satisfaction with data-sharing relationships assessed by CGM-Satisfaction Scale; higher scores are better
Time frame: 6 months post-baseline
Plan to share: Yes — After study results are posted on clinical trials and published, de-identified data will be available upon requests made to the principal investigator.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: After study results are posted on clinical trials and outcomes published in a peer-reviewed journal, until 5 years later.
Access criteria: Contact the principal investigator
Started Apr 2023 (actual). Primary completion is estimated for Jan 2027, 45 months after the start.
Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 45 months is above that.
Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vanderbilt University Medical Center →